Terms ending in 2038
Every in-force patent on Genmab A/S's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,595,316 | Bispecific and Multispecific Antibodies and Method for Isolation of Such In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,091,557 | Methods of Producing Multispecific Antibodies Against CD40 and CD137 In force · High confidence | BioNTech SE | In force | High confidence | |
| US 11,034,772 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,396,553 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · Low confidence | Genmab A/S | In force | Low confidence | |
| US 11,512,137 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,577,316 | Methods of Use of ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,894,833 | Agents, Uses and Methods for Treatment In force · High confidence | H. Lundbeck A/S | In force | High confidence | |
| US 10,968,280 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,459,395 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,673,994 | Humanized or Chimeric CD3 Antibodies In force · High confidence | Genmab A/S | In force | High confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
8 of these are in force and held by Genmab A/S.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.